NIPH Clinical Trials Search

UMIN ID: UMIN000000521

Registered date:14/11/2006

Study on the efficacy of octreotide acetate for cancer-related bowel obstruction

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedcancer-related bowel obstruction
Date of first enrollment2006/10/01
Target sample size50
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by Day 4, dosage is fixed at 300 ug/day until Day 7.


Primary OutcomeAmelioration of abdominal symptoms (subjective parameters)
Secondary Outcome1) Reduction in the number of vomiting episodes and the volume of drainage from a gastric tube (Objective parameters) 2) Correlation between subjective and objective parameters 3) Differences in the efficacy of treatment with octreotide acetate among different cancer types or obstruction sites 4) Assessment of safety in octreotide acetate therapy

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1)Patients with cognitive dysfunction 2)Patients with esophageal obstruction 3)Patients with symptomatic brain metastases or meningeal dissemination 4)Patients undergoing anticancer treatment or radiotherapy within the last 2 weeks 5)Patients judged by the physician in charge to be unsuitable for this study

Related Information


public contact
Name Takayuki Hisanaga
Address Japan
Affiliation Tsukuba Medical Center Hospital Division of Palliative care
scientific contact
Name Ichinosuke Hyodo
Address 1-1-1, Tennoudai, Tsukuba-city, Ibaraki-ken, Japan Japan
Telephone 029-853-3218
Affiliation University of tsukuba Division of Gastroenterology